Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy

Otto Hemminki, Suvi Parviainen, Juuso Juhila, Riku Turkki, Nina Linder, Johan Lundin, Matti Kankainen, Ari Ristimaki, Anniina Koski, Ilkka Liikanen, Minna Oksanen, Dirk M. Nettelbeck, Kalevi Kairemo, Kaarina Partanen, Timo Joensuu, Anna Kanerva, Akseli Hemminki

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalOncotarget
Volume6
Issue number6
Pages (from-to)4467-4481
Number of pages15
ISSN1949-2553
DOIs
Publication statusPublished - 28 Feb 2015
MoE publication typeA1 Journal article-refereed

Fields of Science

  • Oncolytic
  • immunotherapy
  • cancer
  • ATAP
  • CHEMOTHERAPY-REFRACTORY CANCER
  • ANTITUMOR IMMUNE-RESPONSES
  • COLONY-STIMULATING FACTOR
  • ONCOLYTIC ADENOVIRUS
  • OVARIAN-CANCER
  • T-CELL
  • GM-CSF
  • THERAPEUTIC-EFFICACY
  • RETINOIC ACID
  • SOLID TUMORS
  • 3122 Cancers

Cite this